J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells

Vaccine

Volumn 28, Issue 34, 2010, Pages 5533-5542

  Taylor, P R ^a   Koski, G K ^b   Paustian, C C ^b   Bailey, E ^a   Cohen, P A ^c   Moore, F B G ^d   Zimmerman, D H ^e   Rosenthal, K S ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF AKRON   (United States)

^e CEL SCI Corporation   (United States)

Author keywords

Adoptive transfer; Dendritic cells; HIV; HSV; IL12; LEAPS; Th1; Vaccines

Indexed keywords

ASPARTYLLEUCYLLEUCYLLYSYLASPARAGINYLGLYCYLGLUTAMYLARGINYLISOLEUCYLGLUTAMYLLYSYLVALYLGLUTAMIC ACID; CD11 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN D; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; SERYLLEUCYLLYSYLMETHIONYLALANYLASPARTYLPROLYLASPARAGINYLARGINYLPHENYLALANYLARGINYLGLYCYLLYSYLASPARTYLLEUCYLPROLINE; TUMOR NECROSIS FACTOR ALPHA; TYROSYLSERYLVALYLHISTIDYLGLUTAMINYLARGINYLISOLEUCYLASPARTYLVALYLLYSYLASPARTYLTHREONYLLYSYLGLUTAMYLALANYLLEUCYLGLUTAMYLLYSYLISOLEUCYLGLUTAMYLGLUTAMYLGLUTAMYLGLUTAMINYLASPARAGINYLLYSYLSERYLLYSYLLYSYLLYSYLALANINE; UNCLASSIFIED DRUG; VIRUS VACCINE; GLYCOPROTEIN D, HUMAN HERPESVIRUS 1; INTERLEUKIN 12; VIRUS ENVELOPE PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; BONE MARROW CELL; C57BL 6 MOUSE; CELL ACTIVATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SYNTHESIS; EMULSION; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE; A J MOUSE; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CELL CULTURE; DENDRITIC CELL; HERPES SIMPLEX; IMMUNOLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED A; MICE, INBRED C57BL; TH1 CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 77955052320     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.043     Document Type: Article

References (37)

1. Parham P., Androlewicz M., Holmes N., Rothenberg B. Arginine 45 is a major part of the igenic determinant of human beta-2-microglobulin recognized by mouse monoclonal antibody BBM.1. J Biol Chem 1983, 258:6179-6186.
2. Rosenthal K.S. Immune peptide enhancement of peptide based vaccines. Front Biosci 2005, 10:478-482.
3. Goel N., Zimmerman D., Rosenthal K.S. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci 2005, 10:966-974.
4. Zimmerman D.H., Bergmann K.F., Rosenthal K.S., Elliott D.A. A new approach to T cell activation: natural and synthetic conjugates capable of activating T cells. Vaccine Res 1996, 5:91-102.
5. Zimmerman D.H., Morris S., Rouse D., Worthington K.F.W., Elliott D.A., Rosenthal K.S. Immunization with peptide heteroconjugates primes a TH1 associated antibody (IgG2a) response which recognize the native epitope on the 38kDa protein of Mycobacterium tuberculosis. Vaccine Res 1996, 5:103-118.
6. Zimmerman D.H., Rosenthal K.S. The L.E.A.P.S. approach to vaccine development. Front Biosci 2005, 10:790-798.
7. McCalmon R.T., Kubo R.T., Grey H.M. Effect of anti-beta-2-microglobulin on antigen and allogenic lymphocyte-induced proliferation of human lymphocytes. J Immunol 1975, 114:1766-1770.
8. Rosenthal K.S., Mao H., Horne W., Wright C., Zimmerman D. Immunization with a L.E.A.P.S. heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 1999, 17:535-542.
9. Goel N., Rong Q., Zimmerman D., Rosenthal K.S. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 2003, 21:4410-4420.
10. Cihakova D., Barin J.G., Baldeviano G.C., Talor M.V., Zimmerman D.H., Talor E., et al. L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. Int Immunol 2008, 8:624-633.
11. Zimmerman D.H., Taylor P., Bendele A., CArambula R., Duzant Y., Lowe V., et al. CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol 2010, 10:412-421.
12. Zimmerman D.H., Lloyd J.P., Heisey D., Winship M.D., Siwek M., Taylor E., et al. Induction of cross clade reactive antibodies in mice conjugates of HGP-30 peptide analog of HIV-1 (SF2 p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain. Vaccine 2001, 19:4750-4759.
13. Rice W.B. Analyzing tables of statistical tests. Evolution 1989, 43:223-225.
14. Holda J.H. LPS activation of bone marrow natural suppressor cells. Cell Immunol 1992, 141:518-527.
15. Inaba K., Inaba M., Romani N., Ava H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with agranulocytes macrophage stimulating factor. J Exp Med 1992, 176:1693-1702.
16. Cohen P., Koski G., Czerniecki B., Bunting K., Fu X.-Y., Wang Z., et al. Stat 3 and Stat 5 dependent pathways competitively regulate the pan differentiation of CD 34 pos cells into tumor competent dendritic cells. Blood 2008, 112:1832-1843.
17. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
18. Brasel K., De Smedt T., Smith J.L., Maliszewski C.R. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 2000, 96:3029-3039.
19. Maraskovsky E., Brasel K., Teepe M. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand0treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996, 184:1953-1962.
20. Pulendran B. Modulating Th1/Th2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res 2004, 29:187-196.
21. Tamai H., Watanabe S., Zheng R., Deguchi K., Cohen P.A., Koski G.K., et al. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol 2008, 127:66-77.
22. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
23. Snijders A., Kaliniski P., Hilkens C.M., Kaspenberg M.L. High level IL-12 production by human DCs requires 2 signals. Int Immunol 1998, 10(11):1593-1598.
24. Zheng R., Cohen P.A., Paustian C., Johnson T.C., Lee W.T., Shu S., et al. Paired TLR agonists enhance vaccine therapy through induction of IL-12. Cancer Res 2008, 68(11):4045-4049.
25. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lazavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2000, 6:769-776.
26. Mosca P.J., Hobeika A.C., Clay T.M., Nair S.K., Thomas E.K., Morse M.A., et al. A subset of human monocyte-derived DCs expresses high levels of IL-12 in response to combines CD40L and IFN-gamma treatment. Blood 2000, 96(10):3499-3504.
27. Hochrein H., Shortman K., Vremec D., Scott B., Hertzog P., O'Keefe M. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001, 166:5448-5455.
28. Kikly K., Liu L., Na S., Sedgwick J.D. The IL-23/Th17 axis: therapeutic targets of autoimmune inflammation. Curr Opin Immunol 2006, 18:670-675.
29. Annuziato F.L., Cosmi V., Santarlasci L., Maggi F., Liotta B., Mazzinghi E., et al. Phenotypic and functional features of human TH-17 cells. J Exp Med 2007, 204:1849-1861.
30. Mosmann T.R., Moore K.W. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991, 2:49-53.
31. Fiorentino D., Zlotnik A., Vieira P., Mosmann T., Howard M., Moore K., et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991, 146:3444-3451.
32. Taylor A., Akdis M., Joss A., Akkoc T., Wenig R., Colonna M., et al. IL-10 inhibits CD28 and ICOS costimulates of T cells via src homology 2 domain-containing protein tyrosine phosphotase 1. J Allergy Ashthma Res 2007, 12:76-83.
33. Taylor P.R., Paustian C.C., Koski G.K., Zimmerman D.H., Rosenthal K.S. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell Immunol 2010, 262:1-5.
34. Kessler B., Hudrisier D., Schroeter M., Tschopp J., Cerottini J.C., Luescher I.F. Peptide modification of blocking of CD8, resulting in weak TCR signaling, can activate CTL for FAS-but not perforin-dependent cytotoxicity or cytokine production. J Immunol 1998, 161:6939-6946.
35. Kronin V., Vremec D., Winkel K., Classon B.J., Miller R.G., Mak T.W., et al. Are CD8+ dendritic cells (DC) veto cells? The role of CD8 in DC development and in the regulation of CD4 and CD8 T cell responses. Int Immunol 1997, 9:1061-1064.
36. Kronin V., Fitzmaurice C., Caminschi I., Shortman K., Jackson D., Brown L. Differential effect of CD8+ and CD8-dendritic cells in the stimulation of secondary CD4+ T cells. Int Immunol 2001, 13:465-473.
37. Lane P., McConnell F. Dendritic cell subsets and costimulation for effector T-cell responses. Curr Opin Pharmacol 2001, 1:409-416.